Radiopharm Theranostics Ltd (RADX) Receivables (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Receivables of $66605.4 for Q2 2025, up 923.55% year-over-year from $6507.3 in Q2 2024, and up 923.55% quarter-over-quarter from $6507.3 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Receivables (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Receivables for 3 consecutive years, with $66605.4 the latest figure, recorded in Q2 2025.
- In Q2 2025, Receivables rose 923.55% year-over-year to $66605.4; the TTM figure through Jun 2025 stood at $66605.4 (up 923.55% YoY), while the FY2025 annual figure was $66605.4, up 923.55% from the prior year.
- Receivables advanced to $66605.4 in Q2 2025 per RADX's latest filing, from $6507.3 in the prior quarter.
- Across five years, Receivables topped out at $4.5 million in Q2 2023 and bottomed at $6507.3 in Q2 2024.
- Historically, Receivables has averaged $1.5 million across 3 years, with a median of $66605.4 in 2025.
- Annual changes were most pronounced in 2024 — Receivables sank 99.85% — and 2025, when it surged 923.55%.
- Radiopharm Theranostics' Receivables stood at $4.5 million in 2023, then tumbled by 99.85% to $6507.3 in 2024, then soared by 923.55% to $66605.4 in 2025.
- Business Quant data shows RADX's Receivables at $66605.4 in Q2 2025, $6507.3 in Q2 2024, and $4.5 million in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 66,605.44 |
| Jun 30, 2024 | 6,507.29 |
| Jun 30, 2023 | 4.47 Mn |